H. T. Hashim, Jaffer Shah, Ali Talib Hashim, Omar Abdelnasser Abdelmonem Ismail Mohamed, Mahmoud Shaban Abdeljalil, J. Varney
{"title":"The Drugs Used in the Treatment of Supraventricular Tachycardia in Pediatrics: A Systematic Review and Meta-Analysis","authors":"H. T. Hashim, Jaffer Shah, Ali Talib Hashim, Omar Abdelnasser Abdelmonem Ismail Mohamed, Mahmoud Shaban Abdeljalil, J. Varney","doi":"10.33678/cor.2022.097","DOIUrl":null,"url":null,"abstract":"Background: Supraventricular tachycardia (SVT) is an abnormally rapid heart rhythm that results from improper electrical activity in the upper part of the heart. Acute management of children presenting with SVT may be a challenge, as the exact tachycardia mechanism is often unknown. The strategy for treatment depends on the presentation and clinical status of the patient. Methodology: A systematic literature review was conducted to identify and select original research reports on supraventricular tachycardia management drugs in children and infants with no structural heart disease (all children from 1 hour to 17 years of age) in accordance with the PRISMA guidelines. Data were analyzed with Review manager version 5.4. P -value and I 2 were used to test the signifi cance difference. Results: 26 studies out of 65 total studies assessed for eligibility were included in the review by fulfi lling the inclusion criteria. There were 8103 patients from 13 countries with SVT who were treated with different antiarrhythmic drugs including (Adenosine, Dexmedetomidine) as acute management and (Amiodarone, Beta-Blockers, Flecainide, Digoxin and Ivabradine) as chronic control. There was a signifi cant difference between the patients who took the drugs and the patients who responded to the drugs, with P -value <0.005 and I 2 = 72%.","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cor et vasa","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33678/cor.2022.097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 1
Abstract
Background: Supraventricular tachycardia (SVT) is an abnormally rapid heart rhythm that results from improper electrical activity in the upper part of the heart. Acute management of children presenting with SVT may be a challenge, as the exact tachycardia mechanism is often unknown. The strategy for treatment depends on the presentation and clinical status of the patient. Methodology: A systematic literature review was conducted to identify and select original research reports on supraventricular tachycardia management drugs in children and infants with no structural heart disease (all children from 1 hour to 17 years of age) in accordance with the PRISMA guidelines. Data were analyzed with Review manager version 5.4. P -value and I 2 were used to test the signifi cance difference. Results: 26 studies out of 65 total studies assessed for eligibility were included in the review by fulfi lling the inclusion criteria. There were 8103 patients from 13 countries with SVT who were treated with different antiarrhythmic drugs including (Adenosine, Dexmedetomidine) as acute management and (Amiodarone, Beta-Blockers, Flecainide, Digoxin and Ivabradine) as chronic control. There was a signifi cant difference between the patients who took the drugs and the patients who responded to the drugs, with P -value <0.005 and I 2 = 72%.